PAVM
Price
$0.68
Change
+$0.01 (+1.49%)
Updated
May 9 closing price
Capitalization
17.23M
RGEN
Price
$123.24
Change
-$4.61 (-3.61%)
Updated
May 9 closing price
Capitalization
10.26B
86 days until earnings call
Ad is loading...

PAVM vs RGEN

Header iconPAVM vs RGEN Comparison
Open Charts PAVM vs RGENBanner chart's image
PAVmed
Price$0.68
Change+$0.01 (+1.49%)
Volume$153.64K
Capitalization17.23M
Repligen
Price$123.24
Change-$4.61 (-3.61%)
Volume$580.99K
Capitalization10.26B
PAVM vs RGEN Comparison Chart
Loading...
PAVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAVM vs. RGEN commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAVM is a Hold and RGEN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (PAVM: $0.68 vs. RGEN: $123.24)
Brand notoriety: PAVM and RGEN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: PAVM: 121% vs. RGEN: 67%
Market capitalization -- PAVM: $17.23M vs. RGEN: $10.26B
PAVM [@Medical Specialties] is valued at $17.23M. RGEN’s [@Medical Specialties] market capitalization is $10.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAVM’s FA Score shows that 0 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • PAVM’s FA Score: 0 green, 5 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, PAVM is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAVM’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).

  • PAVM’s TA Score: 4 bullish, 5 bearish.
  • RGEN’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, PAVM is a better buy in the short-term than RGEN.

Price Growth

PAVM (@Medical Specialties) experienced а -13.69% price change this week, while RGEN (@Medical Specialties) price change was -12.91% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.49%. For the same industry, the average monthly price growth was +3.17%, and the average quarterly price growth was -3.96%.

Reported Earning Dates

PAVM is expected to report earnings on Mar 24, 2025.

RGEN is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (-1.49% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($10.3B) has a higher market cap than PAVM($17.2M). PAVM YTD gains are higher at: 8.669 vs. RGEN (-14.381). RGEN has higher annual earnings (EBITDA): 134M vs. PAVM (-75.74M). RGEN has more cash in the bank: 751M vs. PAVM (19.6M). PAVM has less debt than RGEN: PAVM (48.7M) vs RGEN (712M). RGEN has higher revenues than PAVM: RGEN (639M) vs PAVM (2.45M).
PAVMRGENPAVM / RGEN
Capitalization17.2M10.3B0%
EBITDA-75.74M134M-57%
Gain YTD8.669-14.381-60%
P/E RatioN/A247.52-
Revenue2.45M639M0%
Total Cash19.6M751M3%
Total Debt48.7M712M7%
FUNDAMENTALS RATINGS
PAVM vs RGEN: Fundamental Ratings
PAVM
RGEN
OUTLOOK RATING
1..100
6758
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
9989
PRICE GROWTH RATING
1..100
6379
P/E GROWTH RATING
1..100
672
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAVM's Valuation (50) in the Medical Specialties industry is somewhat better than the same rating for RGEN (94) in the Biotechnology industry. This means that PAVM’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as PAVM (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to PAVM’s over the last 12 months.

RGEN's SMR Rating (89) in the Biotechnology industry is in the same range as PAVM (99) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to PAVM’s over the last 12 months.

PAVM's Price Growth Rating (63) in the Medical Specialties industry is in the same range as RGEN (79) in the Biotechnology industry. This means that PAVM’s stock grew similarly to RGEN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for PAVM (67) in the Medical Specialties industry. This means that RGEN’s stock grew somewhat faster than PAVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAVMRGEN
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
75%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
70%
View a ticker or compare two or three
Ad is loading...
PAVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FREL27.030.17
+0.63%
Fidelity MSCI Real Estate ETF
DGT141.500.48
+0.34%
SPDR® Global Dow ETF
MBND26.990.03
+0.11%
SPDR® Nuveen Municipal Bond ETF
JIG66.200.02
+0.03%
JPMorgan International Growth ETF
IUSV89.86-0.07
-0.08%
iShares Core S&P US Value ETF

PAVM and

Correlation & Price change

A.I.dvisor tells us that PAVM and GMED have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PAVM and GMED's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAVM
1D Price
Change %
PAVM100%
+1.37%
GMED - PAVM
26%
Poorly correlated
-22.96%
CVRX - PAVM
25%
Poorly correlated
-38.69%
EKSO - PAVM
25%
Poorly correlated
+3.27%
RVTY - PAVM
25%
Poorly correlated
-1.78%
CSTL - PAVM
24%
Poorly correlated
-2.47%
More